Abstract
Alzheimer’s disease (AD) is the most common type of dementia, but its pathogenesis is not fully understood, and effective drugs to treat or reverse the progression of the disease are lacking. Long noncoding RNAs (lncRNAs) are abnormally expressed and deregulated in AD and are closely related to the occurrence and development of AD. In addition, the high tissue specificity and spatiotemporal specificity make lncRNAs particularly attractive as diagnostic biomarkers and specific therapeutic targets. Therefore, an in-depth understanding of the regulatory mechanisms of lncRNAs in AD is essential for developing new treatment strategies. In this review, we discuss the unique regulatory functions of lncRNAs in AD, ranging from Aβ production to clearance, with a focus on their interaction with critical molecules. Additionally, we highlight the advantages and challenges of using lncRNAs as biomarkers for diagnosis or therapeutic targets in AD and present future perspectives in clinical practice.
Funder
Jilin Medical and Health Talents Special Project
Jilin Science and Technology Development Program Project
Jilin Health Care Commission Technological Innovation Project
Subject
Molecular Biology,Biochemistry
Reference198 articles.
1. Alzheimer’s disease;Scheltens;Lancet,2021
2. Haass, C., and Selkoe, D. (2022). If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biol., 20.
3. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics;Karran;Nat. Rev. Drug Discov.,2011
4. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics;Hardy;Science,2002
5. Amyloid beta: Structure, biology and structure-based therapeutic development;Chen;Acta Pharmacol. Sin.,2017
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献